Skip to main content
OpenTrials
Completed

NCT Number: NCT02096718

Afatinib in Subjects With Kidney Dysfunction

The primary objective of the current study is to investigate the influence of moderate to severe renal impairment on the pharmacokinetics and safety of a single dose afatinib in comparison to a control group with normal renal function.

The assessment of safety and tolerability will be an additional objective of this trial and will be evaluated by descriptive statistics.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–79 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

1200.216.1 Boehringer Ingelheim Investigational Site

Kiel, Germany

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Despite renal impairment (group 1 and 2) healthy males or females according to the investigators assessment, as based on the following criteria: a complete medical history including a physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests.
  • Glomerular filtration rate (GFR), estimated according to:

-- MDRD (Modification of Diet in Renal Disease)-formula:

  • eGFR (estimated Glomerular Filtration Rate) [ml/min/1.73m²]= 175 x Serum Creatinine-1.154 x age-0.203 (if male)
  • eGFR[ml/min/1.73m²]= 175 x Serum Creatinine-1.154 x age-0.203 x 0.742 (if female)
  • 30 to 59 mL/min for moderate renal impairment group 1
  • 15 to 29 mL/min for severe renal impairment group 2
  • = 90 mL/min for healthy volunteers group 3
  • Age =18 and =79 years

Exclusion criteria

  • Any finding of the medical examination (including Blood Pressure (BP), Pulse Rate (PR) and Electrocardiogram (ECG)) deviating from normal and of clinical relevance, e.g. repeated measurement of systolic blood pressure < 90 mmHg (millimeter of mercury) or > 140 mmHg, diastolic blood pressure < 50 mmHg or > 90 mmHg, repeated measurement of pulse rate < 45 bpm (beats per minute) or > 90 bpm.
  • Any evidence of a clinically relevant concomitant disease.
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, dermatological or hormonal disorders.
  • Relevant gastrointestinal tract surgery (except appendectomy).
  • Diseases of the central nervous system (such as epilepsy, seizures) or psychiatric disorders or neurological disorders.
  • History of photosensitivity or recurrent rash.
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders.

Treatment and study plan

Afatinib healthy

Drug

Afatinib severe renally impaired

Drug

Afatinib moderate renally impaired

Drug

Primary outcomes

  1. AUC 0-tz of Afatinib (BIBW 2992)

    Time frame: PK plasma samples were taken at: 1 hour before drug administration and 0.5 hour (h), 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 312h after first drug administration

    Area under the concentration-time curve of the analyte in plasma over the time interval from 0 up to the last quantifiable data point

  2. Cmax of Afatinib (BIBW 2992)

    Time frame: PK plasma samples were taken at: 1 hour before drug administration and 0.5 hour (h), 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 312h after first drug administration

    Maximum measured concentration of the analyte in plasma

Secondary outcomes

  1. AUC 0-inf of Afatinib (BIBW 2992)

    Time frame: PK plasma samples were taken at: 1 hour before drug administration and 0.5 hour (h), 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 312h after first drug administration

    Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

Pharmacokinetics, Safety and Tolerability After Single Dose Administration of Afatinib in Moderate and Severe Renal Impairment in Comparison to Subjects With Normal Renal Function (a Mono-centric, Open-label Study in Matched-group Design)

Important dates

Study start
2014
Primary completion
2014
Study completion
2014
First posted
Mar 26, 2014
Registry last updated
Jan 14, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.